does semaglutide make hair fall out Do Ozempic, Wegovy, Mounjaro & Zepbound cause loss? Wegovy & Hair Loss: Does

Novo Nordisk shares slumped on Monday after the drugmaker said the pill version of its weight-loss drug Ozempic had failed to slow the progression of Alzheimers disease in two large studies

"The impurity profiles and, in particular, the evidence of fibril formation in the unapproved 'liraglutide' products raise significant immunogenicity risks and pose serious threats to patients' health," according to the petition

26 January 2026

This might manifest as: Changes in vision, including sudden changes in eyesight Blurry or wavy sight Spots or dark strings floating in your sight (floaters) Dark or empty areas in your vision Visit Memorial Heights ER for Comprehensive Support While GLP-1 drugs offer hope for many struggling with obesity, they are not without risks

A meta-analysis of RCTs in adults with type 1 diabetes showed an increased probability of DKA with SGLT-2 inhibitor therapy compared with placebo (odds ratio 3.38).5 A 2016 review of the existing evidence by an expert panel in Canada found that in T2DM trials, the incidence of DKA was estimated to be 0.160.76 per 1000 patient-years and patients could present with normal blood glucose levels.7 A case series found that about 70% of patients presenting with DKA were euglycemic.7 Overall, data from trials showed that DKA asssociated with SGLT-2 inhibitors occurred more commonly in patients who were dependent on insulin.7 Adverse event databases have also shown that DKA is associated with use of SGLT-2 inhibitors, with over 200 DKA events in adults reported with canagliflozin in Canada11 and 8968 cases of DKA associated with canagliflozin, dapagliflozin or empagliflozin reported in the US,12 of which 15 involved patients under age 18, of whom 3 had T2DM.12 More cases of DKA associated with use of SGLT-2 inhibitors may have gone unreported, and further study in the pediatric population is needed

The glucagon component increases energy expenditure